890 related articles for article (PubMed ID: 22923287)
1. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
[TBL] [Abstract][Full Text] [Related]
2. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F; Papi A; Orlandi M
Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
[TBL] [Abstract][Full Text] [Related]
3. (-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells.
Kim M; Murakami A; Kawabata K; Ohigashi H
Carcinogenesis; 2005 Sep; 26(9):1553-62. PubMed ID: 15860507
[TBL] [Abstract][Full Text] [Related]
4. Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling.
Chen HJ; Lin CM; Lee CY; Shih NC; Amagaya S; Lin YC; Yang JS
Int J Oncol; 2013 Aug; 43(2):629-37. PubMed ID: 23754208
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of invasion and migration by newly synthesized quinazolinone MJ-29 in human oral cancer CAL 27 cells through suppression of MMP-2/9 expression and combined down-regulation of MAPK and AKT signaling.
Lu CC; Yang JS; Chiang JH; Hour MJ; Amagaya S; Lu KW; Lin JP; Tang NY; Lee TH; Chung JG
Anticancer Res; 2012 Jul; 32(7):2895-903. PubMed ID: 22753753
[TBL] [Abstract][Full Text] [Related]
7. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
8. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
9. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met.
Koh YW; Choi EC; Kang SU; Hwang HS; Lee MH; Pyun J; Park R; Lee Y; Kim CH
J Nutr Biochem; 2011 Nov; 22(11):1074-83. PubMed ID: 21292466
[TBL] [Abstract][Full Text] [Related]
10. Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells.
Maeda-Yamamoto M; Suzuki N; Sawai Y; Miyase T; Sano M; Hashimoto-Ohta A; Isemura M
J Agric Food Chem; 2003 Mar; 51(7):1858-63. PubMed ID: 12643642
[TBL] [Abstract][Full Text] [Related]
11. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes.
Singh R; Ahmed S; Malemud CJ; Goldberg VM; Haqqi TM
J Orthop Res; 2003 Jan; 21(1):102-9. PubMed ID: 12507586
[TBL] [Abstract][Full Text] [Related]
13. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex.
Lim YC; Cha YY
J Surg Oncol; 2011 Dec; 104(7):776-80. PubMed ID: 21725973
[TBL] [Abstract][Full Text] [Related]
15. EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest.
Deng YT; Lin JK
J Agric Food Chem; 2011 Dec; 59(24):13318-27. PubMed ID: 22082235
[TBL] [Abstract][Full Text] [Related]
16. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
Matsuo M; Sakurai H; Ueno Y; Ohtani O; Saiki I
Cancer Sci; 2006 Feb; 97(2):155-62. PubMed ID: 16441427
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
[TBL] [Abstract][Full Text] [Related]
18. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
20. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines.
Masuda M; Suzui M; Weinstein IB
Clin Cancer Res; 2001 Dec; 7(12):4220-9. PubMed ID: 11751523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
